EDNRA

Endothelin-1 receptor · P25101 · EDNRA on Sugi Atlas →

67,202 patent compounds predicted against EDNRA, 41,078 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bosentan (SCHEMBL4218)	1.00	20/20
Tezosentan (SCHEMBL4525)	1.00	20/20
SCHEMBL434551	1.00	20/20
Tezosentan (SCHEMBL387773)	0.99	20/20
Bosentan (SCHEMBL615991)	0.98	20/20
Bosentan (SCHEMBL617167)	0.98	20/20
Bosentan (SCHEMBL618415)	0.98	20/20
Bosentan (SCHEMBL622963)	0.98	20/20
Bosentan (SCHEMBL628837)	0.98	20/20
Bosentan (SCHEMBL623792)	0.94	20/20
Bosentan (SCHEMBL625077)	0.94	20/20
SCHEMBL627634	0.86	20/20
SCHEMBL627588	0.81	20/20
Tezosentan (SCHEMBL4524)	0.80	20/20
Tezosentan (SCHEMBL387772)	0.79	20/20
SCHEMBL617288	0.72	20/20
SCHEMBL625550	0.71	20/20
SCHEMBL533208	0.62	20/20
SCHEMBL622949	0.51	20/20
Dimethyl Sulfoxide (SCHEMBL627619)	0.66	19/20

Clinical trials — most relevant to EDNRA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)	PHASE4	UNKNOWN
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.	PHASE3	COMPLETED
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans	PHASE3	COMPLETED
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma	PHASE2	UNKNOWN
Endothelin-1 Receptor Blockade in Resistant Hypertension	PHASE2	RECRUITING
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)	PHASE2	ACTIVE_NOT_RECRUITING
Endothelin-Receptor Blockade in Coronary Heart Disease	PHASE1	COMPLETED
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects	PHASE1	COMPLETED
The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction	PHASE1	COMPLETED
Adiposity and Endothelin Receptor Function	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002	nan	UNKNOWN
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH	nan	COMPLETED
Pharmacogenomics in Pulmonary Arterial Hypertension	nan	WITHDRAWN
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension	nan	RECRUITING
Role of Endothelin-1 in Flow-mediated Dilatation	nan	COMPLETED
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes	nan	COMPLETED
Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.	nan	COMPLETED
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH	nan	WITHDRAWN
Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease	nan	UNKNOWN
Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension	nan	COMPLETED
Menopause Effects on Vascular Function	nan	COMPLETED
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy	nan	COMPLETED
Antecedents of Hypertension: Role of Race and Stress	nan	COMPLETED
Inter-individual Physiological Response to a Training and Detraining Period in Cardiometabolic Risk Factors Subjects	nan	COMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Gap Junction Potentiation of Endothelial Function With Rotigaptide	nan	COMPLETED
Endothelial Effects of VEGF Inhibition In Vivo in Man	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EDNRA binder may also engage these)

Protein	Name	Similarity
Q5KSU9	—	1.000	Q5KSU9 →
Q61614	—	1.000	Q61614 →
P21450	—	1.000	P21450 →
Q29010	—	1.000	Q29010 →
Q95L55	—	1.000	Q95L55 →
P26684	—	0.997	P26684 →
P21451	—	0.984	P21451 →
O62709	—	0.984	O62709 →
P48302	—	0.981	P48302 →
P28088	—	0.977	P28088 →
EDNRB	Endothelin receptor type B	0.977	landscape →
P35463	—	0.977	P35463 →
Q9N0W7	—	0.973	Q9N0W7 →
P56497	—	0.973	P56497 →
GRPR	Gastrin-releasing peptide receptor	0.970	landscape →
P21729	—	0.964	P21729 →
P52500	—	0.963	P52500 →
P24053	—	0.952	P24053 →
O54799	—	0.952	O54799 →
B2ZI34	—	0.952	B2ZI34 →
NMBR	Neuromedin-B receptor	0.952	landscape →
Q95247	—	0.948	Q95247 →
P79350	—	0.942	P79350 →
Q61212	—	0.941	Q61212 →
OPRM1	Mu-type opioid receptor	0.941	landscape →
P42866	—	0.940	P42866 →
Q5IS39	—	0.940	Q5IS39 →
P16177	—	0.939	P16177 →
Q95M54	—	0.939	Q95M54 →
GHSR	Growth hormone secretagogue receptor type 1	0.938	landscape →